Netopia

NetoPia is a biotechnology company focused on the development of novel therapeutics targeting Neutrophil Extracellular Traps (NETs) and the biological process of NETosis. NETs are extracellular fibers composed of DNA and proteins that, while part of the immune response, can drive pathological inflammation and thrombosis when dysregulated. The company leverages its expertise in neutrophil biology to create small molecule inhibitors, particularly targeting Protein-arginine deiminase type IV (PAD4), to treat conditions such as venous thrombosis, chronic wounds, and cancer metastasis. NetoPia's research is grounded in the foundational work of its scientific founders in the field of vascular biology and hematology.